Shares of UCB SA (OTCMKTS:UCBJF – Get Free Report) hit a new 52-week high during trading on Thursday . The company traded as high as $200.00 and last traded at $200.00, with a volume of 35 shares. The stock had previously closed at $197.03.
UCB Stock Performance
The company has a quick ratio of 0.78, a current ratio of 1.19 and a debt-to-equity ratio of 0.33. The firm’s fifty day moving average is $184.31 and its two-hundred day moving average is $170.03.
About UCB
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.
Read More
- Five stocks we like better than UCB
- Investing in Travel Stocks Benefits
- Quantum Opportunity: Skywater Technology’s Long-Term Potential
- 3 Best Fintech Stocks for a Portfolio Boost
- Nebius Group: The Rising Star in AI Infrastructure
- What is the Nasdaq? Complete Overview with History
- MarketBeat Week in Review – 12/30 – 1/03
Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.
